Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.

Abstract:

:Poor therapeutic adherence is a major issue faced by physicians today. This paper summarizes the adherence rates with oral bisphosphonate (OBP) treatment in clinical practice and their impact on clinical outcomes. Studies systematically demonstrated that overall compliance and persistence with OBPs among osteoporotic women are poor. Although extending dosing intervals improved adherence, the gains are suboptimal. Most importantly, low compliance and persistence rates consistently resulted in increased rates of fractures. The results emphasize the importance of adherence to treatment to achieve optimal antifracture efficacy. There is an urgent need to implement strategies and to encourage physicians to take measures that increase patients' awareness of the need to use osteoporosis medications as directed in order to benefit from them fully.

authors

Rabenda V,Hiligsmann M,Reginster JY

doi

10.1517/14656560903140533

subject

Has Abstract

pub_date

2009-10-01 00:00:00

pages

2303-15

issue

14

eissn

1465-6566

issn

1744-7666

journal_volume

10

pub_type

杂志文章,评审
  • A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial - PRASTRO-I trial.

    abstract:BACKGROUND:This comparison of PRAsugrel and clopidogrel in Japanese patients with ischemic STROke (PRASTRO)-I trial investigates the noninferiority of prasugrel to clopidogrel sulfate in the prevention of recurrence of primary events (ischemic stroke, myocardial infarction, and death from other vascular causes), and th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1080/14656566.2018.1444029

    authors: Nagao T,Toyoda K,Kitagawa K,Kitazono T,Yamagami H,Uchiyama S,Tanahashi N,Matsumoto M,Minematsu K,Nagata I,Nishikawa M,Nanto S,Abe K,Ikeda Y,Ogawa A

    更新日期:2018-04-01 00:00:00

  • Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients.

    abstract:INTRODUCTION:Hyperphosphataemia is common in chronic kidney disease (CKD), particularly in the late stages and is associated with secondary hyperparathyroidism, abnormal bone mineralisation and increased cardiovascular morbidity/mortality. At present, there is a range of phosphate binders designed to keep serum phospha...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.928285

    authors: Locatelli F,Dimkovic N,Spasovski G

    更新日期:2014-07-01 00:00:00

  • Transdermal oxybutynin: a new treatment for overactive bladder.

    abstract::Overactive bladder has been successfully treated with oral anticholinergic drugs such as oxybutynin chloride. Although oral oxybutynin has been effective in controlling urinary urge incontinence and in decreasing incontinence episodes, adverse events, particularly dry mouth, often cause patients to discontinue oral th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.12.2315

    authors: Davila GW

    更新日期:2003-12-01 00:00:00

  • Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.

    abstract:INTRODUCTION:In the 40-50% of advanced melanoma patients with tumors harboring BRAF V600E and V600 K mutations, BRAF inhibitors such as dabrafenib are a highly effective treatment. However, most patients develop resistance after several months on treatment. The addition of a MEK inhibitor, such as trametinib, to BRAF i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1168805

    authors: Spain L,Julve M,Larkin J

    更新日期:2016-01-01 00:00:00

  • Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.

    abstract:INTRODUCTION:actinic keratosis is a premalignant disease with a high incidence and is a strong predictor for the development of squamous cell carcinoma. Various treatment options have been established over recent years, including topical treatment with imiquimod, 5-fluorouracil, diclofenac or photodynamic therapy, cryo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.549128

    authors: Quist SR,Gollnick HP

    更新日期:2011-02-01 00:00:00

  • The role of infectious agents in pulmonary and systemic vascular disease.

    abstract::With emphasis on the pulmonary circulation, three general types of vascular disease are discussed: fibroproliferative (atherosclerosis), cellular proliferative (endothelial neoplasms) and inflammatory (granulomatous vasculitis). The causes of these phenotypic responses are invariably multifactorial, but infectious age...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.7.1093

    authors: Egermayer P

    更新日期:2001-07-01 00:00:00

  • Emerging antiretroviral drugs.

    abstract:INTRODUCTION:The potency, tolerability and convenience of antiretroviral agents have all significantly improved over the past years, making lifelong HIV therapy easier. However, several specific needs are still unmet, including low daily pill burden, friendly metabolic profile, lack of (or few) drug interactions and hi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.863277

    authors: Fernández-Montero JV,Vispo E,Soriano V

    更新日期:2014-02-01 00:00:00

  • Empagliflozin for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Despite the availability of numerous anti-diabetes drugs and treatment guidelines, many patients with type 2 diabetes mellitus (T2DM) do not reach recommended targets for glycemic control. There remains an unmet need for effective and well-tolerated anti-diabetes agents that can be used as monotherapy or i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.966078

    authors: Jahagirdar V,Barnett AH

    更新日期:2014-11-01 00:00:00

  • Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.

    abstract:INTRODUCTION:Immune-checkpoint inhibitor (ICPI) drugs, which include antibodies against CTLA-4, PD-1 and PD-L1, have been shown to induce durable complete responses in a proportion of patients with particular efficacy demonstrated in both the first line and refractory setting in advanced NSCLC and melanoma. However, th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1369956

    authors: Flynn MJ,Larkin JMG

    更新日期:2017-10-01 00:00:00

  • Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?

    abstract::Introduction: Multiple sclerosis (MS) is a demyelinating disease, causing axonal damage and disability. Dalfampridine (DAL) is an extended-release formulation of 4-aminopyridine (4AP) and broad-spectrum voltage-dependent potassium channel blocker that is reported to improve motor, visual and cognitive functions. Furth...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2019.1623879

    authors: Foschi M,Lugaresi A

    更新日期:2019-08-01 00:00:00

  • Current and emerging drug treatment strategies for peripheral arterial disease.

    abstract:INTRODUCTION:Peripheral artery disease (PAD) is a prevalent but underdiagnosed manifestation of atherosclerosis that has a worse prognosis than coronary artery disease. Patients with PAD are at heightened risk of both systemic cardiovascular adverse events and limb-related morbidity. There is insufficient awareness of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1774556

    authors: Essa H,Torella F,Lip GYH

    更新日期:2020-09-01 00:00:00

  • Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials.

    abstract::Until recently, atorvastatin was known only as a new but more potent statin ('me too' drug) for lowering low-density lipoprotein cholesterol. In the last 2 years, data has become available on nearly 32,000 patients, in clinical settings ranging from primary prevention to acute coronary syndromes. These trials show the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.6.915

    authors: Ray KK,Cannon CP

    更新日期:2005-06-01 00:00:00

  • The optimal combination therapy for the treatment of early rheumatoid arthritis.

    abstract:INTRODUCTION:Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune condition traditionally viewed as a severe destructive disease affecting physical health and global wellbeing. The treatment strategies for RA have changed in the last decades from mainly symptomatic towards a more vigorous and targeted approac...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1056735

    authors: De Cock D,Van der Elst K,Meyfroidt S,Verschueren P,Westhovens R

    更新日期:2015-01-01 00:00:00

  • Valacyclovir for the treatment of Bell's palsy.

    abstract::Despite recent evidence suggesting that Bell's palsy is associated with reactivation of alfa-herpes viruses, the disease has been treated empirically, and the use of valacyclovir has not been definitively established. In 2007, two prospective, randomised, placebo-controlled trials evaluating valacyclovir were reported...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.9.14.2531

    authors: Hato N,Sawai N,Teraoka M,Wakisaka H,Takahashi H,Hinohira Y,Gyo K

    更新日期:2008-10-01 00:00:00

  • Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy.

    abstract::Introduction: Hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart diseases and represents a leading cause of sudden cardiac death as well as a prevalent cause of heart failure and stroke. HCM is characterized by a very complex pathophysiology, consisting of heterogeneous clinical manifestations a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1702023

    authors: Spoladore R,Fragasso G,Pannone L,Slavich M,Margonato A

    更新日期:2020-02-01 00:00:00

  • New treatment options for panic disorder: clinical trials from 2000 to 2010.

    abstract:INTRODUCTION:Panic disorder (PD) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks. PD patients present significant psychosocial impairment and a high risk of psychiatric comorbidities and suicide. PD should be treated effectively as soon as the symptoms emerge because the long...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.562200

    authors: Freire RC,Hallak JE,Crippa JA,Nardi AE

    更新日期:2011-06-01 00:00:00

  • Asthma therapy during pregnancy.

    abstract::Numerous pregnant women suffer from asthma and the use of asthma medications during pregnancy may be a necessity. Although some information is known about the effects of asthma medications during pregnancy, there is still a significant amount of information to learn and particular attention is required when prescribin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.7.1019

    authors: Demoly P,Piette V,Daures JP

    更新日期:2003-07-01 00:00:00

  • Pharmacotherapy for the prevention of malaria in pregnant women: currently available drugs and challenges.

    abstract:INTRODUCTION:Malaria in pregnancy continues to be a significant public health burden globally, with over 100 million women at risk each year. Sulfadoxine-pyrimethamine (SP) is the only antimalarial recommended for intermittent preventive therapy in pregnancy (IPTp) but increasing parasite resistance threatens its viabi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1526923

    authors: Moore BR,Davis TME

    更新日期:2018-11-01 00:00:00

  • Emerging pharmacotherapeutic agents for insomnia: a hypnotic panacea?

    abstract::The burden of insomnia has had a significant effect not only on the socioeconomic matrix, but also the medical terrain, as signified by the increased morbidity and mortality of its associated psychiatric and organic sequelae. To this end, a plethora of pharmacotherapeutic agents have been recently introduced that addr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.13.1731

    authors: Navab P,Guilleminault C

    更新日期:2006-09-01 00:00:00

  • Pharmacological treatment of generalized anxiety disorder.

    abstract:INTRODUCTION:Generalized anxiety disorder (GAD) is a chronic, relapsing, debilitating disorder, associated with markedly impaired social and occupational functioning. Pharmacological treatment is considered standard care and several drug classes are now FDA approved for the treatment of GAD. While there are clear data ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.618496

    authors: Reinhold JA,Mandos LA,Rickels K,Lohoff FW

    更新日期:2011-11-01 00:00:00

  • Vinflunine for the treatment of breast cancer.

    abstract:INTRODUCTION:Breast cancer is the most frequently diagnosed cancer and the highest cause of cancer mortality in females worldwide. The development of drugs improving overall survival in late-stage metastatic breast cancer remains a challenge. Vinflunine is the most recently developed drug in the vinca alkaloid class. I...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1217991

    authors: Gourmelon C,Bourien H,Augereau P,Patsouris A,Frenel JS,Campone M

    更新日期:2016-09-01 00:00:00

  • Pharmacotherapy for the treatment of vaginal atrophy.

    abstract:INTRODUCTION:Despite its frequency, recognition and therapy of vulvovaginal atrophy (VVA) remain suboptimal. Wet mount microscopy, or vaginal pH as a proxy, allows VVA diagnosis in menopause, but also in young contraception users, after breast cancer, or postpartum. Intravaginal low dose estrogen product is the main th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1574752

    authors: Donders GGG,Ruban K,Bellen G,Grinceviciene S

    更新日期:2019-05-01 00:00:00

  • Ramipril in the treatment of vascular diseases.

    abstract::Ramipril is an angiotensin-converting enzyme inhibitor that has been extensively studied in randomised, controlled clinical trials in patients with cardiovascular diseases. Therapy with ramipril in patients with various cardiovascular disorders has demonstrated significant and clinically important reductions in cardio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.11.1911

    authors: Rokoss MJ,Teo KK

    更新日期:2005-09-01 00:00:00

  • Treatment of adult short bowel syndrome patients with teduglutide.

    abstract:INTRODUCTION:Parenteral support is lifesaving in short bowel syndrome patients with intestinal failure (SBS-IF), who are unable to compensate for their malabsorption by metabolic or pharmacologic adaptation. Mutually, the symptoms of SBS-IF and the inconveniences and complications in relation to parenteral support may ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.644787

    authors: Nørholk LM,Holst JJ,Jeppesen PB

    更新日期:2012-02-01 00:00:00

  • Nonbiological pharmacotherapies for the treatment of diabetic macular edema.

    abstract:INTRODUCTION:During the past decade, there have been significant advances in the pharmacotherapies for the treatment of diabetic macular edema (DME). Among the presently available treatment options, anti-vascular endothelial growth factors (anti-VEGF) agents are the most favored agents due to their efficacy and safety....

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1100172

    authors: Agarwal A,Parriott J,Demirel S,Argo C,Sepah YJ,Do DV,Nguyen QD

    更新日期:2015-01-01 00:00:00

  • Advances in orally administered pharmacotherapy for the treatment of migraine.

    abstract:INTRODUCTION:Migraine is a common and highly disabling neurological disorder whose acute treatment remains problematic and unsatisfactory in a high percentage of cases. Consequently, there remains a need for new symptomatic therapies that can be easily handled by patients (i.e. by oral administration). AREAS COVERED:T...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1549223

    authors: Martelletti P,Giamberardino MA

    更新日期:2019-02-01 00:00:00

  • Iontophoretic transdermal fentanyl for the management of acute perioperative pain in hospitalized patients.

    abstract:INTRODUCTION:Intravenous (I.V.) morphine administered through a patient-controlled system currently represents the gold standard treatment for moderate to severe acute postoperative pain. To fix the limitations showed by the available I.V. patient-controlled analgesia (PCA) systems that may restrict its use in the clin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1146684

    authors: Fanelli A,Sorella MC,Chelly JE

    更新日期:2016-01-01 00:00:00

  • Anti-TNF-alpha therapy in ankylosing spondylitis.

    abstract::Ankylosing spondylitis (AS) is a frequent disease leading to functional impairment and socioeconomic burden. Anti-TNF-alpha therapy has brought new perspectives in this condition. Two agents are currently used in the treatment of AS and spondyloarthropathies - infliximab (a chimeric monoclonal antibody) and etanercept...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.7.1497

    authors: Wendling D,Toussirot E

    更新日期:2004-07-01 00:00:00

  • Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.

    abstract:INTRODUCTION:Increasing population age, obesity and physical inactivity mean that type 2 diabetes mellitus (T2DM) is increasingly common. Current treatments may be limited by adverse events, drug-drug interactions or contraindication/need for dose adjustment in patients with renal impairment. AREAS COVERED:This paper ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.642863

    authors: Forst T,Pfützner A

    更新日期:2012-01-01 00:00:00

  • Management of incomplete remission and treatment resistance in first-episode psychosis.

    abstract:BACKGROUND:Incomplete remission and treatment resistance are common even in first-episode psychosis patients. OBJECTIVE:The aim of this review was to provide an overview of the available interventions and treatment pathways for the management of incomplete remission and treatment resistance in first-episode psychosis....

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.12.2039

    authors: Lambert M,Naber D,Huber CG

    更新日期:2008-08-01 00:00:00